CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01745120
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:17.874939+00:00
Published At: 2019-05-08T00:00:00+00:00
Record Updated At: 2019-05-08
Results Posted At: 2019-05-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["\u03b2-thalassemia Major"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-05-08"
protocolSection.identificationModule.nctId: "NCT01745120"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With \u03b2-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral \u03b2A-T87Q-Globin Vector (LentiGlobin\u00ae BB305 Drug Product)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-05-08"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.